ARID1B and non-small cell lung carcinoma: Interestingly, Sun et al.—who enrolled 240 patients—observed that NSCLC patients who harbored AT-rich interacting domain-containing protein 1A gene (ARID1A) mutations or AT-rich interacting domain-containing protein 1B gene (ARID1B) mutations had a beneficial response to anti PD-(L)1 immunotherapy and a prolonged PFS [47].